Skip to main content
. 2020 Mar 4;12:1611–1619. doi: 10.2147/CMAR.S240469

Figure 3.

Figure 3

(A) Comparison between the SALL4 expression levels of mrd+ (patients who are resistant to therapy) and mrd− (patients who are sensitive to therapy) ALL patients. Significant increased SALL4 expression levels in mrd+ ALL patients compared with the drug-sensitive, mrd−, group (****P<0.0001). (B) SALL4 was identified to be significantly overexpressed in the relapsed patients in comparison with the mrd− cases (***P=0.0002).